论文部分内容阅读
目的分析探讨阿托他汀类药物对急性脑梗死的临床疗效及安全性。方法选择2010年7月至2011年7月在我院就诊的急性脑梗死患者126例,将全部患者随机分为观察组和对照组各63例,对照组予复方丹参20ml静脉滴注,1次/d,连用14d。观察组在对照组治疗基础上加用阿托伐他汀口服治疗,20mg/d,连用14d,观察记录两组临床疗效及不良反应。结果观察组的总有效率为87.30%,对照组为69.84%,观察组总有效率显著高于对照组,两者比较差异有统计学意义(P<0.05);观察组的ADL、神经功能缺损评分均显著优于对照组(P<0.05)。结论阿托伐他汀在常规治疗基础上应用对急性脑梗死有较好的疗效和安全性,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of atorvastatin in acute cerebral infarction. Methods A total of 126 acute cerebral infarction patients treated in our hospital from July 2010 to July 2011 were randomly divided into observation group (63 cases) and control group (63 cases), and control group (20ml) / d, used in conjunction 14d. The observation group was treated with atorvastatin orally at a dose of 20 mg / d on the basis of the control group for 14 days, and the clinical efficacy and adverse reactions were observed and recorded in both groups. Results The total effective rate was 87.30% in the observation group and 69.84% in the control group, and the total effective rate in the observation group was significantly higher than that in the control group (P <0.05). The ADL and neurological deficit The score was significantly better than the control group (P <0.05). Conclusion Atorvastatin on the basis of routine treatment of acute cerebral infarction has a good effect and safety, worthy of clinical application.